Video transcript
Small molecules that you cannot make with medicinal chemistry, or you cannot isolate enough of in nature. That chemical sweet spot in the middle, that's where we will operate first. It's so foundational, the change we have made by removing the cell from cell-based SynBio, and we therefore had to build a lot of foundational tools to even have a functional first system.
The good news is that we are now with a platform that is so powerful that we can start applying ourselves into different applications and in those different verticals getting to product and, from a business point of view, getting to revenue.
The first applications we're making from the platform is focused on getting us to the first value inflection points. It doesn't necessarily have to be the finished product, but it has to be a, now we can do this that wasn't possible before, and therefore that creates value, or it at least allows people to realize a lot of value will be created in the future.
We're therefore focusing on products where we need in volume relatively little while still creating a lot of value. Instead of necessarily starting to address all applications, we're therefore focusing in on what we think of as better medicines - you can argue that's drugs - and nutraceuticals.
When we talk about better medicines and nutraceuticals, we are often talking about molecules that already exist in nature, but in tiny, tiny amounts. So imagine a molecule that is, for example, in a plant or other places in nature, but that you would need an extreme amount of it, and you would need to put a lot of money and effort into isolating this tiny, tiny, tiny amount only to have enough for one treatment.
Yeah, you can do that one time. You can maybe do it a handful of times or enough that you can show by preclinical and clinical studies that this is the medicine that can help or maybe even cure a disease. But what does it help if we can't scale it? It's almost a tease. What is unique about our system is, of course, that we can be inspired by these natural pathways. We can reconstitute them outside of their cells.
We can put them in scalable biomanufacturing systems as biosolutions, and that way making things available that otherwise wasn't available before. Every time there is a rule, there's an exception. So we have just talked about how the different first applications are better medicines and nutraceuticals.
But, of course, when you have a really good partner that shows up and is willing to go against the stream and says, we understand that biofuels and sustainable aviation fuel is not better medicines, it's not nutraceuticals, but it's going to take such a long journey that we need to get started now so we have it in the near future and not in the far, far away future.
We have that partner in the U.S. government and more specifically, for example, the DoE that has been a great partner coming to us and saying, we would like you to stay with the course of building isobutanol to sustainable aviation fuel in the future.
So as an application, that is our exception to the rule. We have a great partner. It's going to take a long time. It's not something we could survive on as a business if it was the only application we were working on because it's so far away from significant revenues. But at the same time, it is a worthy course.
When we build a biosolution that we understand really well, that has a relative easy path to market or a path we understand really well, we will do them as spin-outs. We will basically take the biosolution as an asset, spin it out in a fully owned subsidiary that is though set up with its own brand, its own team, sometimes its own financing depending on if there's a need for that, meaning external financing. If we don't want to finance all of it ourselves. And with that, basically go to market directly.
We will, in some cases, do spin-outs, but together with other people. We'll do them as joint ventures. It basically means we have found a partner that often have market insight, market access, maybe bring another technology or commercial asset to the table that together we can with our biosolution enables a new business.
We will out-license our technology as biosolutions to partners and customers. We are already in deep conversations and relationship with companies that are owners of existing markets and setups where they're identifying our new generation of biomanufacturing will enable everything from new competitive advantages such as lower prices, better products, more innovative solutions, new features, more sustainable setups, and so forth.
And they basically come to us and are pointing out the opportunity between our technology as a biosolution and all of their setup. Another example of how we are looking for partners and collaborators are all the amazing companies that have been working so hard and diligently on SynBio.
They have figured out exactly what their pathway that makes a specific compound or chemical that is amazing in a specific market, but they got stuck inside of the cell. We love when we in collaboration can help liberate that system from the cell and the limitations and move it over to exozyme biosolutions.
And in combination of our platform can take all the knowledge and opportunity, all the hard work people have put into their SynBio solutions and allowing people to get to market with something that makes a real life impact.
Concrete examples of biosolutions we're going to build first are natural products that doesn't exist in enough volume in nature, but that we can make available. They are small molecules that you cannot make with medicinal chemistry. You cannot isolate enough of in nature. That chemical sweet spot in the middle, that's where we will operate first.
We have a number of compounds in mind. We have a number of partners we are talking with about putting these things first in the R&D phases of actually putting the pathway together and after that in production systems that allows us to have the full biosolution.
Forward-Looking Statements
This collateral contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond eXoZymes' control. eXoZymes' actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent eXoZymes' views as of the date of this press release. eXoZymes anticipates that subsequent events and developments will cause its views to change. eXoZymes undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing eXoZymes' views as of any date subsequent to the date of this release.
